Boston Scientific’s Cyberattack Cuts Guidance And Warns Of 2027 ‘Trough’ As FARAWAVE Ultra, FARAFLEX
Boston Scientific reduced its full-year outlook due to a cyberattack in August. CEO Mike Mahoney warned that 2027 may be a challenging year, with delayed product launches and soft demand. The company expects lower sales and adjusted EPS in 2024, excluding certain items.
How this was made
The 30-second read
Why it matters
The key incremental signal is managements explicit 2027 trough expectation and the slip of next pulsed field ablation launches into 2028, alongside still-soft WATCHMAN demand.
Market read
A guidance reset plus a multi-year trough and launch-delay warning changes the forward growth profile and increases downside risk to medtech procedure-cycle expectations.
What to watch
The article excerpt does not quantify the magnitude of the guidance cut or the specific adjusted EPS details, so traders should verify the exact revised outlook and any mitigation actions post-attack.
Background
Boston Scientific experienced an August cyberattack that knocked back third-quarter growth, prompting a full-year outlook cut.
Ticker impact
Boston Scientific cut its full-year outlook after an August cyberattack and warned 2027 will be the trough as PFA launches slip into 2028.
Likely downside pressure as investors reprice the 2027 trough narrative and the delayed PFA launch cadence.
The article attributes a guidance cut to the cyberattack and adds a specific CEO outlook for 2027 trough timing, which directly affects forward revenue and earnings expectations.
Market effects
Raises perceived execution and demand-cycle risk for cardiac rhythm and ablation procedure device makers, especially around launch timing and procedure volumes.
Primarily US-listed medtech sentiment; could spill into broader healthcare device risk appetite.
Cyberattack-driven operational disruption narrative can affect global medtech supply-chain and IT resilience risk premiums.
Counterpoint
The trough framing may already be partially anticipated; if WATCHMAN demand stabilizes and PFA launches re-accelerate after 2028, the market may over-discount the longer-term cycle.
Key entities
- companyBoston Scientific
Medtech company whose guidance was cut after a cyberattack and whose CEO warned 2027 will be the trough in the cycle.
- personMike Mahoney
CEO who stated 2027 will be the trough and discussed launch timing and demand challenges.
- productFARAWAVE Ultra and FARAFLEX
Pulsed field ablation platforms referenced as having launch timing slipping into 2028.
- productWATCHMAN
Cardiac device demand described as still soft.
